<DOC>
	<DOC>NCT00317954</DOC>
	<brief_summary>The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.</brief_summary>
	<brief_title>Spironolactone in Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Diabetes Mellitus Diabetic Nephropathy Glomerular filtration rate &gt; 30 ml/min/1.73 m2 Blood pressure &gt; 130/80 mm Hg Child bearing potential Plasmapotassium &gt;4.5 mmol/l Breastfeeding Abuse of alcohol or drugs Nondiabetic kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Aldosterone antagonism</keyword>
	<keyword>Renoprotection</keyword>
</DOC>